Reuters logo
3 months ago
BRIEF-Mabvax Therapeutics presents positive early stage data on pancreatic cancer treatment
June 5, 2017 / 11:36 AM / 3 months ago

BRIEF-Mabvax Therapeutics presents positive early stage data on pancreatic cancer treatment

June 5 (Reuters) - Mabvax Therapeutics Holdings Inc -

* Mabvax Therapeutics phase i trial results of antibody therapy mvt-5873 for the treatment of advanced pancreatic cancer presented at the 2017 asco annual meeting

* Mabvax Therapeutics Holdings Inc - one-third of patients with advanced pancreatic cancer achieve stable disease with a complete response reported

* Mabvax Therapeutics Holdings Inc - highlighted that single agent mvt-5837 appears safe and well tolerated in patients at biologically active doses​

* Mabvax Therapeutics Holdings Inc - single agent mvt-5873 appears safe and tolerable at biologically active doses Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below